519 results on '"Garcia Tsao G"'
Search Results
2. Early trends in cystatin c and outcomes in patients with cirrhosis and acute kidney injury
3. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation
4. Ascites
5. List of Contributors
6. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
7. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis : A pilot study (RIFA-AH)
8. Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974, (S0168827821022996), (10.1016/j.jhep.2021.12.022)]
9. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES
10. Supplement to: Management of varices in cirrhosis
11. Supplement to: Management of varices and variceal hemorrhage in cirrhosis
12. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club
13. Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal Hypertension
14. Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment
15. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
16. Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis
17. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis
18. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine
19. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders
20. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis
21. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine
22. Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite
23. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
24. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)
25. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility
26. Chapter 36 - Ascites
27. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
28. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
29. 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH
30. Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
31. A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
32. Thrombelastography-Guided Blood Product Use Before Invasive Procedures in Cirrhosis With Severe Coagulopathy: A Randomized, Controlled Trial
33. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation
34. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes
35. Hyponatremia and Hepatorenal Syndrome
36. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
37. 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis
38. In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation
39. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis
40. Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients
41. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients
42. LBP-019 - 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH
43. LBO-001 - A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
44. GS-015 - Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
45. Prognostic benefit of the addition of an electroencephalographic (EEG) index to the MELD score: the MELD-EEG
46. Editorial - Women in hepatology: Who and why
47. In-Hospital Mortality Related to Hepatic Encephalopathy is Independent of Acute-On-Chronic Liver Failure and Varies Significantly across North America: Nacseld Experience
48. Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival
49. Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis
50. Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.